Skip to content
Auranofin
Ridaura (auranofin) is a small molecule pharmaceutical. Auranofin was first approved as Ridaura on 1985-05-24. It is used to treat pemphigus, psoriatic arthritis, and rheumatoid arthritis in the USA. It is known to target transient receptor potential cation channel subfamily A member 1.
Download report
Favorite
Commercial
Therapeutic Areas
Therapeutic Area
MeSH
musculoskeletal diseasesD009140
skin and connective tissue diseasesD017437
immune system diseasesD007154
Trade Name
FDA
EMA
Ridaura
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Auranofin
Tradename
Company
Number
Date
Products
RIDAURASebela PharmaceuticalsN-018689 RX1985-05-24
1 products, RLD, RS
Labels
FDA
EMA
Brand Name
Status
Last Update
ridauraNew Drug Application2018-12-14
Indications
FDA
EMA
Indication
Ontology
MeSH
ICD-10
pemphigusEFO_1000749D010392L10
psoriatic arthritisEFO_0003778D015535L40.5
rheumatoid arthritisEFO_0000685D001172M06.9
Agency Specific
FDA
EMA
No data
Patent Expiration
No data
ATC Codes
M: Musculo-skeletal system drugs
— M01: Antiinflammatory and antirheumatic products
— M01C: Specific antirheumatic agents
— M01CB: Gold preparations
— M01CB03: Auranofin
HCPCS
No data
Clinical
Clinical Trials
44 clinical trials
View more details
Mock data
Subscribe for the real data
Indications Phases 4
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
MalariaD008288EFO_0001068B5434—5314
Falciparum malariaD016778EFO_0007444B502222713
Hiv infectionsD015658EFO_0000764B201421311
RabiesD011818A82———1—1
PharmacokineticsD010599———1—1
ExerciseD015444EFO_0000483———1—1
Indications Phases 3
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Pneumocystis pneumoniaD011020EFO_0007448B59132—28
Indications Phases 2
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Cerebral toxoplasmosisD016781EFO_0007200B58.2—1——12
Covid-19D000086382U07.1—1———1
Bacterial infectionsD001424A49—1———1
Indications Phases 1
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Non-small-cell lung carcinomaD0022892————2
HivD006678O98.71————1
ToxoplasmosisD014123EFO_0007517B581————1
Myeloid leukemia acuteD015470C92.01————1
Gastroesophageal refluxD005764EFO_0003948K211————1
Biological availabilityD0016821————1
Indications Without Phase
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
InfectionsD007239EFO_0000544————22
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
Drug common nameAURANOFIN
INNauranofin
Description
Auranofin is a gold salt classified by the World Health Organization as an antirheumatic agent. It has the brand name Ridaura.
Classification
Small molecule
Drug class—
Image (chem structure or protein)
Structure (InChI/SMILES or Protein Sequence)
CC(=O)OC[C@H]1O[C@@H]([S-])[C@H](OC(C)=O)[C@@H](OC(C)=O)[C@@H]1OC(C)=O.CCP(CC)CC.[Au+]
Identifiers
PDB—
CAS-ID34031-32-8
RxCUI1227
ChEMBL IDCHEMBL1366
ChEBI ID2922
PubChem CID16667669
DrugBankDB00995
UNII ID3H04W2810V (ChemIDplus, GSRS)
Target
Agency Approved
No data
Alternate
TRPA1
TRPA1
Organism
Homo sapiens
Gene name
TRPA1
Gene synonyms
ANKTM1
NCBI Gene ID
8989
Protein name
transient receptor potential cation channel subfamily A member 1
Protein synonyms
ankyrin-like with transmembrane domains 1, Ankyrin-like with transmembrane domains protein 1, p120, Transformation-sensitive protein p120, Wasabi receptor
Uniprot ID
O75762
Mouse ortholog
Trpa1 (277328)
transient receptor potential cation channel subfamily A member 1 (Q8BLA8)
Variants
Clinical Variant
No data
Financial
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Additional graphs summarizing 3,911 documents
View more details
Safety
Black-box Warning
Black-box warning for: Ridaura
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
3,951 adverse events reported
View more details